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Abstract
Background: Worldwide, over 10 million people are killed or hospitalized because of traumatic brain injury each
year. About 90% of deaths occur in low- and middle-income countries. The condition mostly affects young adults,
and many experience long lasting or permanent disability. The social and economic burden is considerable.
Tranexamic acid (TXA) is commonly given to surgical patients to reduce bleeding and the need for blood
transfusion. It has been shown to reduce the number of patients receiving a blood transfusion by about a third,
reduces the volume of blood transfused by about one unit, and halves the need for further surgery to control
bleeding in elective surgical patients.
Methods/design: The CRASH-3 trial is an international, multicenter, pragmatic, randomized, double-blind,
placebo-controlled trial to quantify the effects of the early administration of TXA on death and disability in patients
with traumatic brain injury. Ten thousand adult patients who fulfil the eligibility criteria will be randomized to
receive TXA or placebo. Adults with traumatic brain injury, who are within 8 h of injury and have any intracranial
bleeding on computerized tomography (CT scan) or Glasgow Coma Score (GCS) of 12 or less can be included if the
responsible doctor is substantially uncertain as to whether or not to use TXA in this patient. Patients with significant
extracranial bleeding will be excluded since there is evidence that TXA improves outcome in these patients.
Treatment will entail a 1 g loading dose followed by a 1 g maintenance dose over 8 h.
The main analyses will be on an ‘intention-to-treat’ basis, irrespective of whether the allocated treatment was
received. Results will be presented as appropriate effect estimates with a measure of precision (95% confidence
intervals). Subgroup analyses for the primary outcome will be based on time from injury to randomization, the
severity of the injury, location of the bleeding, and baseline risk. Interaction tests will be used to test whether the
effect of treatment differs across these subgroups. A study with 10,000 patients will have approximately 90%
power to detect a 15% relative reduction from 20% to 17% in all-cause mortality.
Trial registration: Current Controlled Trials ISRCTN15088122; Clinicaltrials.gov NCT01402882
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Background
Worldwide, over 10 million people are killed or hospi-
talized because of traumatic brain injury (TBI) each year
[1]. Approximately 90% of deaths from TBI occur in
low- and middle-income countries [2]. TBI predomin-
antly affects young adults, and many patients experience
long lasting or permanent disability. The social and eco-
nomic burden of TBI is considerable. With rapidly in-
creasing motorization, the incidence of TBI is predicted
to rise in low- and middle-income countries [3]. An ef-
fective, widely practicable and affordable treatment for
TBI could save many thousands of lives and substantially
reduce the burden of disability.
The antifibrinolytic agent tranexamic acid (TXA) is
commonly given to surgical patients to reduce bleeding
and the need for blood transfusion. A systematic review
of randomized trials of TXA in elective surgical patients
shows that TXA reduces the number of patients receiv-
ing a blood transfusion by about one-third, reduces the
volume of blood transfused by about one unit, and halves
the need for further surgery to control bleeding [4]. These
differences are all highly statistically significant. Further-
more, there is no evidence of any increased risk of vas-
cular occlusive events with TXA [4].
More recently, TXA has been shown to reduce mortal-
ity in trauma patients with significant extracranial bleed-
ing. The CRASH-2 trial, which enrolled 20,211 bleeding
trauma patients from hospitals in 40 countries, showed
that the administration of TXA within 8 h of injury sig-
nificantly reduces deaths due to bleeding ((RR Relative
Risk) = 0.85, 95% confidence interval (CI) 0.76 to 0.96;
P= 0.008), and all-cause mortality (RR= 0.91, 95% CI
0.85 to 0.97; P= 0.0035) compared to placebo, with no
apparent increase in vascular occlusive events [5]. Among
patients treated very soon after injury, the reduction in
mortality with TXA is even greater [6]. Cost-effectiveness
analysis has shown that the administration of TXA to
bleeding trauma patients is highly cost effective in low-,
middle- and high-income settings [7]. As a consequence
of the CRASH-2 trial results, TXA has been incorpo-
rated into trauma treatment protocols worldwide and
has been included on the World Health Organization
(WHO) List of Essential Medicines.
The knowledge that TXA reduces blood loss in sur-
gery and reduces mortality in traumatic bleeding raises
the possibility that it might also be effective in TBI. In-
tracranial hemorrhage is common after TBI, and is asso-
ciated with increased mortality and disability. In the
Medical Research Council (MRC) CRASH-1 trial, which
included 10,008 TBI patients, 73% of patients with mod-
erate or severe TBI had intracranial hemorrhage on com-
puterized tomography (CT) scan [8]. Hemorrhage size is
strongly associated with outcome. Patients with a large
intracranial hemorrhage, whatever the location, have a
substantially higher mortality than patients with a small
hemorrhage [9]. In many TBI patients, the intracranial
bleeding continues after hospital admission [10,11]. Among
patients with moderate or severe TBI, who are found to
have intracranial bleeding on a CT scan taken soon after
hospital admission, intracranial bleeding progresses in
84% of patients.
Approximately one-third of patients with TBI have la-
boratory evidence of abnormal coagulation at hospital
admission [12]. These patients have an increased risk of
intracranial hemorrhage and higher mortality. Increased
fibrinolysis, as indicated by high levels of fibrinogen deg-
radation products, is common in TBI and is a strong in-
dependent predictor of progressive intracranial hemorrhage
[13]. These observations raise the possibility that TXA
might reduce intracranial hemorrhage and improve out-
come in TBI patients.
In addition, it has been shown that progressive tissue
damage and edema develops in regions surrounding in-
tracranial bleeding lesions, and is associated with a worse
outcome [14]. Tissue plasminogen activator (tPA) has
been shown to be an important factor in this process of
peri-lesional edema [15-17]. By blocking the conversion
from plasminogen to plasmin, TXA counteracts the ef-
fect of tPA and, therefore, it is possible that TXA might
also be beneficial in traumatic intracerebral hemorrhage
by decreasing peri-lesional edema through a specific neu-
roprotective effect.
Two studies have evaluated the effect of TXA in trau-
matic brain injury. The CRASH-2 Intracranial Bleeding
Study was a nested, randomized trial conducted in 270
trauma patients who had evidence of TBI on a pre-
randomization CT scan. A second scan was conducted
24 to 48 h after randomization. There was a reduction
in intracranial hemorrhage growth (RR = 0.80; 95% CI
0.59 to 1.09), fewer ischemic lesions and lower all-cause
mortality (RR = 0.60; 95% CI 0.32 to 1.11) in TXA allo-
cated patients, but these results were not statistically sig-
nificant [18]. A second randomized trial conducted in
240 patients with isolated TBI also found reductions in
hemorrhage growth (RR= 0.56; 95% CI 0.32 to 0.97) and
mortality (RR= 0.67; 95% CI 0.34 to 1.32) with TXA, but
this trial did not collect data on ischemic lesions [19].
Meta-analysis of the two trials shows a significant reduc-
tion in hemorrhage growth (RR = 0.72; 95% CI 0.55 to
0.94) and mortality (RR = 0.63; 95% CI 0.40 to 0.99)
with TXA.
Although the results from these trials are promising,
the estimates are imprecise and there are no data on the
effect of TXA on disability. Furthermore, because pa-
tients in the CRASH-2 Intracranial Bleeding Study also
had significant extracranial bleeding, the extent to which
the results can be generalized to patients with isolated
TBI is open to question. The CRASH-3 trial will provide
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reliable evidence about the effect of TXA on mortality
and disability in patients with TBI. The effect of TXA on
the risk of vascular occlusive events and seizures will
also be assessed. If such a simple and widely practicable
treatment was shown to improve outcomes in patients
with TBI, then it could be used in high-, middle- and
low-income countries, saving many thousands of lives
and reducing the burden of disability.
Objective
The CRASH-3 trial will provide reliable evidence as to
whether the antifibrinolytic agent TXA can reduce mor-
tality and disability in patients with traumatic brain
injury.
Methods, design, discussion
Overview
The CRASH-3 trial is an international, multicenter,
pragmatic, randomized, double-blind, placebo-controlled
trial to quantify the effects of the early administration
(within 8 h of injury) of TXA on death and disability in
TBI patients. A total of 10,000 adult TBI patients who
fulfil the eligibility criteria will be randomized to receive
either TXA or placebo. The eligibility criteria are based
on the uncertainty principle (Figure 1).
Pragmatic design and the uncertainty principle
The pragmatic design will allow us to find out how ef-
fective the treatment actually is in routine everyday prac-
tice. Ethically, this randomized controlled trial can only
be undertaken if there is collective scientific uncertainty
about which of the interventions being compared is
more likely to benefit patients [20,21]. However, for an
individual clinician to be able to recommend enrolment
of a patient into a trial, they must be substantially uncer-
tain about the appropriateness of the trial treatment in
that particular patient. The eligibility criteria for the
CRASH-3 trial are based on this uncertainty principle.
This approach to assessing trial eligibility is well estab-
lished [22].
A patient can be enrolled if, and only if, the respon-
sible clinician is substantially uncertain as to which of
the trial treatments would be most appropriate for that
particular patient. A patient should not be enrolled if the
responsible clinician or the patient (or his/her represen-
tative) are for any medical or non-medical reasons rea-
sonably certain that one of the treatments that might be
allocated would be inappropriate for this particular indi-
vidual (in comparison with either no treatment or some
other treatment that could be offered to the patient in
or outside the trial). Using the uncertainty principle
should allow the process of this trial to be closer to what
is appropriate in normal medical practice.
Eligible patients
Adults with TBI who are within 8 h of injury, with any
intracranial bleeding on CT scan, or, if no scan is avail-
able, who have a Glasgow Coma Score (GCS) of 12 or
less, and no significant extracranial bleeding (that is, not
in need of immediate blood transfusion) are eligible, if
Figure 1 Trial Overview.
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the responsible clinician is substantially uncertain as to
the appropriateness of TXA for them. The fundamental
eligibility criterion is the responsible clinician’s ‘uncer-
tainty’ as to whether or not to use TXA in a particular
patient with TBI. This pragmatic approach will allow us
to see whether the intervention improves patient out-
comes under real-life conditions.
Although some increase in the risk of vascular occlu-
sive events (arterial or venous thrombosis) might be
expected with TXA on theoretical grounds, clinical trials
in trauma patients have not found any increase [4-6]. In
the CRASH-2 trial, in which 20,211 trauma patients
were randomly assigned within 8 h of injury to either
TXA (loading dose 1 g over 10 min followed by infusion
of 1 g over 8 h) or placebo, there were fewer vascular oc-
clusive events in patients allocated to receive TXA (168
(1.7%) TXA versus 201 (2.1%) placebo; RR= 0.84; 95%
CI 0.68 to 1.02).
Because TXA is eliminated by renal excretion there is
a risk of accumulation in patients with renal impairment.
However, because the CRASH-3 trial involves a very short
course of TXA (a loading dose followed by an infusion
over 8 h) the risk of accumulation should be minimal.
Although high doses of TXA have been associated with
seizures in patients undergoing cardiac surgery, there were
no reports of serious unexpected adverse events involving
seizures in the 20,211 trauma patients randomized into
the CRASH-2 trial, half of whom received the dose of
TXA that is being used in the CRASH-3 trial [23].
Even though there are no absolute contraindications
to TXA administration in patients with traumatic brain
injury, patients with TBI should only be enrolled if their
doctor is reasonably ‘uncertain’ as to whether or not to
use TXA for that particular patient. The summary of
product characteristics for TXA and an Investigator’s
Brochure will be provided to investigators to ensure that
they have the information needed to assess the balance
of harms and benefits in each patient.
Randomization
Patients will receive all-usual treatment for TBI. Patients
eligible for inclusion should be randomized and the
study treatment started as soon as possible. The Entry
Form (Additional file 1: Form 1) will be used to assess
eligibility and collect baseline information. The next
consecutively numbered treatment pack, taken from a
box of eight packs, should then be chosen. Once a pa-
tient has been randomized, outcome data need to be col-
lected even if the trial treatment is interrupted or is not
actually given.
Follow-up
No extra tests are required for the trial but an Outcome
Form (Additional file 2: Form 2) should be completed 28
days after randomization, or at death or hospital dis-
charge if either happens sooner. Short-term disability will
be assessed on the Outcome Form using the Disability
Rating Scale (DRS). This scale measures the level of dis-
ability in six diagnostic categories of (1) eye opening, (2)
best verbal response, (3) best motor response, (4) self-
care ability for feeding, grooming and toileting, (5) level
of cognitive functioning, and (6) employability, and can
be used across the span of recovery. The maximum
score a patient can obtain is 29, which represents an ex-
treme vegetative state. A person without disability would
score zero [24].
We will also assess specific patient orientated out-
comes that have been identified by patients and their
families as being important. They were identified from
the literature and then considered and agreed by patient
representatives from RoadPeace, the UK national charity
for those killed or injured in road crashes.
Settings
Patients will be recruited from hospitals in high-, middle-
and low-income countries. There is no limit to the max-
imum number of patients to be recruited at each site.
Number of patients needed
Two main factors determine the number of patients
needed in a trial: the estimated event rate and size of the
treatment effect. The primary end point for CRASH-3 is
death in hospital within 28 days.
Estimated event rate
In the CRASH-1 trial, among patients with moderate or
severe TBI (GCS of 12 or less), the risk of death in the
control group was approximately 20%.
Sample size and size of treatment effect that should
be detectable
A study with 10,000 TBI patients would have about 90%
power (two sided alpha = 1%) to detect a 15% relative re-
duction (from 20% to 17%) in all-cause mortality. With
10,000 patients, the study would also have over 90%
power to detect a difference in mean DRS score of 1.0
(assuming a SD of DRS of 9.0). Experience from the
CRASH-1 and CRASH-2 trials suggests that the antici-
pated rates of loss to follow-up (less than 1%) would not
impact importantly on study power.
Recruitment of collaborating investigators
The trial will recruit hospitals from many countries
around the world and we will continue to add hospitals
throughout the trial until the sample size is achieved.
Suitable collaborating hospitals and investigators will be
assessed in terms of the trauma service that they provide
and their ability to conduct the trial. Before the trial can
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begin at any site, the local Principal Investigator must
agree to adhere to Good Clinical Practice Guidelines
and all relevant national regulations. In addition, all rele-
vant regulatory and ethics approvals should be in place
before the trial starts at a site.
Ethical considerations, information giving and written
informed consent
The Glasgow Coma Score (GCS) is a method of asses-
sing the level of consciousness in TBI patients. Patients
with a GCS score of 15 are generally considered fully
conscious, but those with a GCS score of 12 or less are
not fully conscious and would not be mentally capable
of giving informed consent to participation in a clinical
trial. Intracranial bleeding is a clinical sign indicating
significant brain injury, and patients with this diagnosis
would not be physically or mentally capable of giving
informed consent to participation in a clinical trial.
Therefore, given that patients are eligible for inclusion
in the CRASH-3 trial if they have sustained a traumatic
brain injury and have either intracranial bleeding on a
CT scan or a GCS of 12 or less, they will, by default, be
physically or mentally incapable of giving consent.
Traumatic brain injury is an emergency condition that
requires urgent treatment. Because intracranial bleeding
occurs soon after injury, any treatment needs to be given
as soon as possible. There is evidence from trials in trau-
matic extracranial bleeding that TXA is more effective
when given early [25]. The need for urgent treatment in
the CRASH-3 trial means that the implementation of
the research cannot be delayed and that it would be in-
appropriate to delay treatment until fully informed consent
can be obtained from a relative or other legal repre-
sentative. Patients who are incapable of giving consent
in emergency situations are an established exception to
the general rule of informed consent in clinical trials.
This is clearly acknowledged in the Declaration of
Helsinki.
“Research involving subjects who are physically or men-
tally incapable of giving consent, for example, uncon-
scious patients, may be done only if the physical or
mental condition that prevents giving informed consent is
a necessary characteristic of the research population. In
such circumstances the physician should seek informed
consent from the legally authorized representative. If no
such representative is available if the research cannot be
delayed, the study may proceed without informed consent
provided that the specific reasons for involving subjects
with a condition that renders them unable to give in-
formed consent have been stated in the research protocol
and the study has been approved by a research ethics
committee. Consent to remain in the research should be
obtained as soon as possible from the subject or a legally
authorized representative.” (WMA Declaration of Helsinki
2008 – Ethical Principles for Medical Research Involving
Human Subjects)
The following procedure which is in accordance with
the Declaration of Helsinki will be used for giving infor-
mation and obtaining informed consent for the CRASH-
3 trial (Figure 2).
Prior information giving
If relatives are present, bearing in mind the clinical situ-
ation and their level of distress, they will be provided
with brief information about the trial. Specifically, the
responsible doctor will explain to the relatives that the
patient will receive the usual emergency treatments for
traumatic brain injury but that, in addition to these, the
patient has been enrolled in a research study that aims
to improve the treatment of patients with this condition.
It will be explained that the study is being done to see
whether using a drug called TXA will help patients with
head injury by reducing the amount of bleeding into the
brain, therefore preventing further brain damage. The
relative will be informed that the patient will be given an
infusion into a vein over 8 h of either TXA or a dummy
medicine (a liquid which does not contain TXA). The
doctor will explain that TXA has been shown to improve
outcome in patients with other types of severe injury
and that, whilst we hope that it will also improve recov-
ery after head injury, at present we cannot be sure about
this. Further information will only be provided on re-
quest. If requested, a brief information sheet will be pro-
vided (Additional file 3: Form 3). If relatives object to
the inclusion of the patient in the trial, their views will
be respected. If no relatives are present, two doctors
(one independent of the trial) will consider the patient’s
eligibility criteria and any known views of the patient about
trial participation. Together they will decide whether or
not to enrol the patient into the trial. Examples of the
information sheets and consent forms to be used are given
in the additional files provided (Additional file 4 and 5).
Randomization
Randomization codes will be generated and secured by an
independent statistical consultant from Sealed Envelope
Ltd (London, UK). The codes will be made available to a
GMP certified clinical trial supply company explicitly for
the treatment packs to be created in accordance with the
randomization list. Eligibility will be determined from the
routinely collected clinical information and no trial specific
tests are required. Patients eligible for inclusion should be
randomized to receive either TXA or placebo (sodium chlo-
ride 0.9%) and the trial treatment started as soon as possible.
Baseline information will be collected on the Entry
Form (Additional file 1: Form 1) and the next lowest
consecutively numbered pack will be taken from a box
of eight treatment packs. When the treatment ampoules
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are confirmed as being intact, the patient is considered
to be randomized into the trial. The entry form data will
be sent to the Trial Coordinating Centre as soon as pos-
sible after entry. Once a patient has been randomized,
the outcome of the patient should be obtained even if
the trial treatment is interrupted or is not actually given.
Treatment
TXA will be compared with matching placebo (sodium
chloride 0.9%).
Dose selection
TXA has been used to reduce bleeding in elective sur-
gery for many years. A systematic review of randomized
trials of TXA in surgery shows that dose regimens of TXA
vary widely [4]. Loading doses range from 2.5 mg/kg to
100 mg/kg and maintenance doses from 0.25 mg/kg/h to
4 mg/kg/h delivered over periods of 1 to 12 h. Studies
examining the impact of different doses of TXA on bleeding
and transfusion requirements showed no significant dif-
ference between a high dose and a low dose [4,26].
In emergency situations, the administration of a fixed
dose is more practicable because weighing patients in
such situations is difficult. In the CRASH-3 trial, a fixed
dose of 1 g loading dose of TXA, followed by a 1 g
maintenance dose over 8 h has been selected. This fixed
dose is within the dose range which has been shown to
inhibit fibrinolysis and provide hemostatic benefit. It
should be efficacious for larger patients (>100 kg) but
also safe in smaller patients (<50 kg), as the estimated
dose/kg that the latter group would receive has been
used in other trials without adverse effects. Furthermore,
this fixed dose was used in 20,211 patients enrolled in
the CRASH-2 trial and was found to be both effective
and safe. The same fixed dose was also used in two stud-
ies of TXA in TBI patients, again with no evidence of
adverse effects.
Drug manufacture, blinding and supply of trial treatment
The active trial drug TXA (CyklokapronW Injection) will
be purchased on the open market. TXA is manufactured
by Pfizer Ltd under Marketing Authorization Number
Figure 2 Consent procedure diagram.
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PL00032/0314. The Marketing Authorization guarantees
that the product has been manufactured and released in
accordance with the UK Good Manufacturing Regulations.
Placebo (sodium chloride 0.9%) will be manufac-
tured specially to match the TXA by a GMP certified
manufacturer.
Ampoules and packaging will be identical in appear-
ance. The blinding process and first stage Qualified Per-
son (QP) release will be done by the designated clinical
trial supply company. The blinding process will involve
complete removal of the original manufacturer’s label
and replacement with the clinical trial label bearing the
randomization number which will be used as the pack
identification. Other pack label text will be identical for
both TXA and placebo treatments and will be in compliance
with requirements for investigational medicinal products.
The designated clinical trial supply company will also
be responsible for maintaining the Product Specification
File (PSF) until final database lock and unblinding of the
trial data. Quality control checks to assure the blinding
process will be performed on a random sample of final
QP released drug packs. High-performance liquid chro-
matography (HPLC) analyses, separation of known TXA,
will be assessed against blinded samples to confirm
which ampoule contains the placebo and active treat-
ments. The tested samples will be unblinded to assure
accuracy of blinding.
The Trial Coordinating Centre (TCC) will be respon-
sible for assuring all relevant approvals are available at
the TCC before release of the trial treatment to a site. A
separate Manual of Operating Procedures will detail the
drug accountability system. The Investigator’s Brochure
will detail labeling of the trial treatment and other pro-
cesses for assuring adherence to Good Manufacturing
Practice.
Administration of trial treatment
Each treatment pack will contain:
 4 × 500 mg ampoules of TXA or placebo
 2 × sterile 10 mL syringe and 21FG needle
Loading dose
2 ampoules = 1 g – added to 100 mL sodium chloride
0.9% and infused over 10 minutes.
Maintenance dose
2 ampoules = 1 g – Added to 500 mL of any isotonic
intravenous solution and infused at 120 mg/h (60 mL/h)
for about 8 h.
The trial treatment injections should not be mixed
with blood for transfusion, or infusion solutions contain-
ing penicillin or mannitol.
Other treatments for traumatic brain injury
There is a wide spectrum of treatments for TBI. As the
trial will be conducted worldwide, each participating site
should follow its own clinical guidelines for the treat-
ment of TBI patients. There is no need to withhold any
clinically indicated treatment in this trial. TXA or pla-
cebo would be provided as an additional treatment to
the usual management of TBI.
Adverse events
TXA has a well documented safety profile. Although the
Summary of Product Characteristics suggests that rare
cases of thromboembolic events might be associated with
TXA administration, there is no evidence that the TXA
treatment regimen used in this trial is associated with an
increased risk of vascular occlusive events. Nevertheless,
data on vascular occlusive events and seizures will be
collected as secondary outcomes and will be presented
to the independent Data Monitoring Committee (DMC)
for unblinded review.
Definitions
Adverse event: Any untoward medical occurrence af-
fecting a trial participant during the course of a clinical
trial
Serious Adverse Event (SAE): A serious adverse
event (experience) is any untoward medical occurrence
that results in death, is life-threatening, requires inpa-
tient hospitalization or prolongation of existing hospi-
talization, or results in persistent or significant disability/
incapacity.
Adverse Reaction: An adverse event when there is at
least a possibility that it is causally linked to a trial drug
or intervention
Serious Adverse Reaction (SAR): SAE that is thought
to be causally linked to a trial drug or intervention
Suspected Unexpected Serious Adverse Reaction
(SUSAR): An unexpected occurrence of a SAR; there
need only be an index of suspicion that the event is a
previously unreported reaction to a trial drug or a previ-
ously reported but exaggerated or unexpectedly frequent
adverse drug reaction.
Reporting of adverse events for this trial
Death, life-threatening complications, and prolonged
hospital stay are pre-specified outcomes to be reported
in this trial and also to the independent DMC. This clin-
ical trial is being conducted in a critical emergency con-
dition using a drug in common use. It is important to
consider the natural history of the critical medical event
affecting each patient enrolled, the expected complica-
tions of this event, and the relevance of the complica-
tions to TXA.
Adverse events to be reported using an adverse event
reporting form will be limited to those not already listed
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as primary or secondary outcomes, but which might rea-
sonably occur as a consequence of the trial drug. Events
that are part of the natural history of the primary event
of TBI or expected complications of TBI should not be
reported as adverse events.
If an SAE, SAR or SUSAR occurs, a written report
must be submitted within 24 h. Advice for investigators
on reporting of adverse events is available by calling the
TCC Emergency Helpline. The TCC will coordinate the
reporting of all SAEs/SARs/SUSARs to all relevant Reg-
ulatory Agencies, Ethics Committees and local investiga-
tors as per local legal requirements.
Unblinding
In general there should be no need to unblind the allo-
cated treatment. If some contraindication to TXA devel-
ops after randomization (for example, clinical evidence
of thrombosis), the trial treatment should simply be
stopped and all usual standard care given. Unblinding
should be done only in those rare cases when the clin-
ician believes that clinical management depends import-
antly upon knowledge of whether the patient received
TXA or placebo. In those few cases when urgent un-
blinding is considered necessary, a 24-h telephone
service will be available and details provided in the
Investigator’s Study File and wall posters. The caller will
be told whether the patient received TXA or placebo.
An unblinding report form should be completed by the
investigator and sent to the Trial Coordinating Centre
within 1 working day.
Measures of outcome
After a patient has been randomized, outcome in hos-
pital will be collected even if the trial treatment is in-
terrupted or is not actually given. No extra tests are
required but a short Outcome Form (Additional file 2:
Form 2) will be completed 28 days after randomization,
or at prior death or discharge from the randomizing
hospital.
Primary outcome
The primary outcome is death in hospital within 28 days
of injury (cause-specific mortality will also be recorded).
Secondary outcomes
a) Vascular occlusive events (myocardial infarction
(MI), pulmonary embolism (PE), clinical evidence of
deep vein thrombosis (DVT))
b) Stroke
c) Disability assessed using the DRS and Patient
Orientated Outcome measures
d) Seizures
e) Neurosurgical intervention
f ) Days in intensive care
g) Other adverse events will be described
Cost effectiveness analysis
A cost-utility analysis performed from a health care per-
spective will be conducted. Although the constraints of a
large pragmatic trial reduce the scope for a compre-
hensive economic evaluation, the precise estimates of
treatment effects from such studies are an important ad-
vantage. Data from the CRASH-3 trial will be used to
populate a decision analytic model. The assessment of
incremental cost effectiveness requires an estimate of
health care costs and QALYs with and without adminis-
tration of TXA. The incremental cost will be estimated
using the data available at 28 days or discharge on ICU
days, non-ICU days and health care interventions. If
there are any significant differences in vascular events
(PE, DVT, MI), stroke, or operative intervention, these
can be used to refine the estimate of difference in cost.
Life years gained will be modeled using the data on
death or discharge in the first 28 days. Initially, it will be
assumed that patients at discharge and those in hospital
at 28 days have the life expectancy of their age-gender
group. However, it will be important to explore alterna-
tive assumptions. Any significant differences in compli-
cations between the two treatment groups could be used
to improve the estimate. Although CRASH-3 will not
collect quality-of-life data directly, the detailed classifica-
tion of the patient’s condition at discharge or 28 days
can be used as the basis for a quality-of-life adjustment.
Separate estimates of the incremental cost effectiveness
ratio will be produced for the subgroups identified in the
trial protocol. Some of the uncertainty surrounding the
estimated cost effectiveness will be examined using de-
terministic and probabilistic sensitivity analysis.
Data collection and management
This trial will be coordinated from the TCC at the London
School of Hygiene & Tropical Medicine (LSHTM) and
conducted in hospitals in low-, middle- and high-income
countries. Data will be collected at each site by local
investigators and sent to the TCC. Only data outlined on
the entry, outcome, unblinding report and adverse event
forms will be collected in this trial.
The entry form (Additional file 1: Form 1) will be used
before randomization to confirm eligibility and collect
baseline data. The outcome form (Additional file 2:
Form 2) will be completed 28 days after randomization
or at prior death or hospital discharge. These data will
be collected from the patient’s routine medical records
and no special tests will be required.
If a patient or their representative withdraws a previ-
ously given informed consent or refuses to consent for
continuation in the trial, or if the patient dies and no
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consent is available, the patient’s data will be handled as
follows:
 Data collected up to the point of withdrawal will be
used in an intention-to-treat analysis.
 All data on adverse events, including those routinely
collected as outcomes, will be collected and
reported as required by the relevant authorities.
To allow for variation in available technology for data
transfer, a variety of data collection methods will be used
in the trial. Data will be collected by the investigator on
paper case report forms (CRFs) and transmitted to the
TCC either by fax or email or by entering the data dir-
ectly into the trial database. Original paper CRFs will
remain at each trial site. The data will be used in ac-
cordance with local law and ethics committee approval.
Monitoring
ICH GCP section 5.18.3 states in regard to monitoring
that “the determination of the extent and nature of moni-
toring should be based on considerations such as the ob-
jective, purpose, design, complexity, blinding, size and
endpoints of the trial. In general there is a need for on-site
monitoring, before, during, and after the trial; however in
exceptional circumstances the sponsor may determine
that central monitoring in conjunction with procedures
such as investigators training and meetings, and exten-
sive written guidance can assure appropriate conduct of
the trial in accordance with GCP. Statistically controlled
sampling may be an acceptable method for selecting the
data to be verified.”
The CRASH-3 trial is a large, pragmatic, randomized,
double-blind, placebo -controlled trial. The intervention
(TXA) has marketing authorization in many countries
and has been in clinical use for decades. Its safety profile
is well established and no significant serious adverse
events associated with its use have been identified. The
trial will routinely collect data on adverse events which
may theoretically be associated with this product and
the condition under investigation, and these will be re-
viewed by the independent DMC. The trial procedures
are based on routine clinical procedures and include (1)
the intravenous administration of the trial drug using
routine clinical use; (2) collecting routine clinical infor-
mation from the medical records; and (3) informed con-
sent. There are no complex procedures or interventions
for the participants or investigators in this trial. Clinical
management for underlying conditions will remain as
per each hospital’s standard protocol. Based on these fac-
tors, the probability of harm or injury (physical, psycho-
logical, social or economic) occurring as a result of
participation in this research study has been assessed as
low in each of these categories. Based on the low risks
associated with this trial, the Monitoring Procedure to
assure appropriate conduct of the trial will utilize 100%
central data monitoring in conjunction with procedures
such as investigator training and meetings and written
guidance. In addition, all data will be subject to statis-
tical monitoring and approximately 10% of data will be
subjected to on-site monitoring. Consent Forms will be
monitored centrally by the TCC (where permission is
given to do so). Investigators/institutions are required to
provide direct access to source data/documents for trial-
related monitoring, audits, ethics committee review and
regulatory inspection. All trial-related and source docu-
ments must be kept for at least 5 years after the end of
the trial.
End of trial for participants
For the recruited patients the trial ends at death, hos-
pital discharge or at 28 days follow-up, whichever occurs
first. If during the treatment phase a patient develops an
adverse event, the trial drug should be stopped, the pa-
tient treated in line with local procedures, and then fol-
lowed up. The trial may be terminated early by the Trial
Steering Committee (TSC).
The independent DMC may give advice/recommenda-
tion for the early termination of the trial but the TSC is
responsible for the final decision.
Analysis
The main analyses will compare all those allocated TXA
versus those allocated placebo, on an ‘intention-to-treat’
basis, irrespective of whether they received the allocated
treatment or not. Results will be presented as appropri-
ate effect estimates (relative risks and absolute risks)
with a measure of precision (95% CI). Subgroup analyses
for the primary outcome will be based on time from in-
jury to randomization, the severity of TBI (moderate or
severe), the location of the intracranial bleeding, and
baseline risk. Interaction tests will be used to test wheth-
er the effect of treatment (if any) differs across these
subgroups. Unless there is strong evidence against the
null hypothesis of homogeneity of effects (that is, P
< 0.001), the overall relative risk will be considered as
the most reliable guide to the approximate relative risks
in all subgroups. Between-sites heterogeneity in effect-
iveness will also be explored.
A secondary analysis will be conducted in which the
primary outcome will be adjusted by age, pupil reac-
tivity, blood pressure and GCS. Because all secondary
outcomes are non-fatal, the effect of TXA on these out-
comes could be affected by competing risk by death. We
will tackle this potential problem using the principal
stratification method for studies with censoring due to
death as proposed by Rubin [27]. A detailed Statistical
Analysis Plan setting out full details of the proposed
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analyses will be finalized before the trial database is
locked for final analysis.
Sponsorship and trial management
The CRASH-3 trial is sponsored by the LSHTM and its
responsibilities coordinated by the TCC. The TCC may
delegate responsibilities to third parties which will be
outlined in relevant agreements. The responsibilities of
the TCC will be overseen by the Trial Management
Group (TMG).
Indemnity
LSHTM accepts responsibility attached to its sponsor-
ship of the trial and, as such, would be responsible for
claims for any non-negligent harm suffered by anyone as
a result of participating in this trial. The indemnity is
renewed on an annual basis and LSHTM assures that it
will continue renewal of the indemnity for the duration
of this trial.
Protocol development
The Protocol Committee consists of the following inves-
tigators who are responsible for the development of, and
agreeing to, the final protocol. Subsequent changes to
the final protocol will require the agreement of the TSC.
 Chief investigator: Professor Ian Roberts
 Clinical experts: Professor Yashbir Dewan,
Dr Jorge H Mejía-Mantilla, Dr Edward Komolafe,
Dr Pablo Perel
 Trial management: Ms Haleema Shakur
 Statistician: Dr Phil Edwards
Independent Data Monitoring Committee
 Dr Samuel C. Ohaegbulam, Neurosurgeon-in-Chief,
Memfys Hospital for Neurosurgery, Nigeria,
Neurosurgery
 Professor Anthony Rodgers, George Institute,
Australia, Clinical Trials
 Professor Mike Clarke, University of Belfast, UK,
Epidemiology and statistics
To provide protection for study participants, an inde-
pendent DMC has been appointed for this trial to oversee
the safety monitoring. The DMC will review, on a regular
basis, accumulating data from the ongoing trial and advise
the TSC regarding the continuing safety of current partici-
pants and those yet to be recruited, as well as reviewing
the validity and scientific merit of the trial.
The DMC composition, name, title and address of the
chairman and of each member, will be given in the
DMC Charter. Membership includes expertise in the
relevant field of study, statistics and research study de-
sign. An independent statistician will be appointed to
provide the analysis service required by the DMC. The
DMC Charter includes, but is not limited to, defining:
a) the schedule and format of the DMC meetings
b) the format for presentation of data
c) the method and timing of providing interim reports
d) stopping rules
Standard operating procedures
The DMC has the responsibility for deciding whether,
while randomization is in progress, the unblinded results
(or the unblinded results for a particular subgroup),
should be revealed to the TSC. The DMC Charter states
that they will do this if, and only if, the following two
conditions are satisfied: (1) the results provide proof be-
yond reasonable doubt that treatment is on balance ei-
ther definitely harmful or definitely favourable for all, or
for a particular category of participants in terms of the
major outcome; and (2) the results, if revealed, would be
expected to substantially change the prescribing patterns
of clinicians who are already familiar with any other trial
results that exist. Exact criteria for “proof beyond rea-
sonable doubt” are not, and cannot be, specified by a
purely mathematical stopping rule, but they are strongly
influenced by such rules. The DMC Charter is in agree-
ment with the Peto-Haybittle stopping rule whereby an
interim analysis of a major endpoint would generally
need to involve a difference between treatment and con-
trol of at least three standard errors to justify premature
disclosure [28,29]. An interim subgroup analysis would,
of course, have to be even more extreme to justify dis-
closure. This rule has the advantage that the exact number
and timing of interim analyses need not be pre-specified.
In summary, the stopping rules require extreme differ-
ences to justify premature disclosure, and involve an ap-
propriate combination of mathematical stopping rules
and scientific judgment.
Trial steering committee
 Professor Peter Sandercock (Chair), Western
General Hospital; Professor of Medical Neurology,
Director, Edinburgh Neuroscience, University of
Edinburgh, UK (randomized control trials, conduct
of large scale international trials)
 HB Hartzenberg, Tygerberg Academic Hospital,
Faculty of Health Sciences, University of
Stellenbosch, South Africa; Professor and Head of
Neurosurgery (previous President of the Society of
Neurosurgeons of South Africa)
 Amy Aeron-Thomas, Executive Director, RoadPeace,
the national charity for road crash victims, London,
UK (Expertise includes developing national road
safety action plans, costing crashes and documenting
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their socio-economic impact on families. Road safety
pilot project in Nigeria, intended to improve
compensation for road crash victims and increase
awareness of the road traffic injury burden.)
 Manjul Joshipura, Scientist (trauma care),
World Health Organization, Geneva, Switzerland
(Scientific leadership and technical support in the
field of trauma care to the WHO; previous Director
of Academy of Traumatology, India)
 Ian Roberts, London School of Hygiene & Tropical
Medicine, London, UK; Professor of Epidemiology
(randomized control trials; conduct of large scale
international trials)
 Pablo Perel, London School of Hygiene & Tropical
Medicine, London, UK; Clinical Lecturer
(randomized control trials; trial methodology)
 Haleema Shakur, London School of Hygiene &
Tropical Medicine, London, UK; Senior Lecturer (trial
methodology; randomized control trials; conduct of
large scale international trials)
The role of the TSC is to provide overall supervision
of the trial. In particular, the TSC will concentrate on
the progress of the trial, adherence to the protocol, pa-
tient safety and consideration of new information. The
TSC must be in agreement with the final protocol and,
throughout the trial, will take responsibility for:
a) major decisions such as a need to change the
protocol for any reason
b) monitoring and supervising the progress of the trial
c) reviewing relevant information from other sources
d) considering recommendations from the DMC
e) informing and advising the TMG on all aspects of the trial
The Steering Committee consists of people with ex-
perience in clinical trials, traumatic brain injury research
and patient representatives. Face-to-face meetings will
be held at regular intervals determined by need, but no
less than once a year. A TSC Charter will be agreed at
the first meeting and will detail how the committee will
conduct its business.
When outcome data are available for 500 trial partici-
pants, the TSC will review the rate of recruitment into
the trial and the overall event rates. The TSC will con-
sider the extent to which the rate of recruitment and the
event rates correspond to those anticipated before the
trial and will take whatever action is needed in light of
this information.
Advisory committees
An ad hoc advisory group was established at the
protocol development stage of the CRASH-3 trial with
the responsibility of ensuring the protocol was appro-
priate to populations in a wide variety of settings.
Clinicians and clinical trialists (including neurosur-
geons and other trauma specialists) from UK, Colombia,
India and Nigeria were consulted during face-to-face
meetings in each country and their input was incorpo-
rated in the final protocol. The members of the advisory
group are listed at the trial website (http://crash3.lshtm.ac.
uk/a).
In addition, an International Advisory Committee (IAC)
will be convened to fulfil two roles:
(a) to advise the TMG on matters relevant to the trial,
and
(b)to enable appropriate representation of each
country’s views on the trial.
The role of the IAC is advisory only. The IAC will
constitute the National Coordinators from participating
countries and other individuals with relevant expertise.
The IAC will be chaired by the Chair of the TMG. New
members will be added as new countries join the trial
and National Coordinators are appointed. The IAC will
provide advice and comments to the TMG. The TMG
will inform the TSC accordingly on matters raised by
the IAC that relate either to the protocol or which might
have an impact on the progress of the trial. The TMG
will convey any relevant comments from the IAC to the
TCC on matters relating to the day-to-day management
of the trial. An important function of the IAC is to fa-
cilitate the sharing of experience and best practice be-
tween its members on how best to conduct the trial
efficiently within each country and how to overcome bar-
riers to progress. The IAC’s chief role is therefore to report
on the progress of the trial within each country and to pro-
vide advice to the TMG, TSC and TCC in order to
maximize the efficiency of the trial’s conduct, and hence
the chances of completing the trial on time and within
budget.
Collaborators’ responsibilities
Coordination within each participating hospital will be
through a local Principal Investigator whose responsibil-
ity will be detailed in an agreement in advance of start-
ing the trial and will include:
 Ensure all necessary approvals are in place prior to
starting the trial
 Delegate trial-related responsibilities only to suitably
trained and qualified personnel
 Train relevant medical and nursing staff who see
TBI patients and ensure that they remain aware of
the state of the current knowledge, the trial and its
procedures (there are wall charts, pocket
summaries and training presentations to assist
with this)
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 Agree to comply with the final trial protocol and
any relevant amendments
 Ensure that all patients with TBI are considered
promptly for the trial
 Ensure consent is obtained in line with local
approved procedures
 Ensure that the patient entry and outcome data are
completed and transmitted to the TCC in a timely
manner
 Ensure the Investigator’s Study File is up to date and
complete
 Ensure all adverse events are reported promptly to
the TCC
 Be accountable for trial treatments at their site
 Ensure the trial is conducted in accordance with
ICH GCP and fulfils all national and local regulatory
requirements
 Allow access to source data for monitoring, audit
and inspection
 Be responsible for archiving all original trial
documents, including the data forms, for 5 years
after the end of the trial
Trial management group and Trial Coordinating Centre
responsibilities
The TMG will consist of at least the following members:
Chief Investigator, a trial manager and a clinical expert.
The TCC will act on behalf of the Sponsor and will be
responsible to the TMG to ensure that all Sponsor’s re-
sponsibilities are carried out. The responsibilities will in-
clude (but are not limited to):
 Reporting to the TSC
 The day-to-day management of the trial
 Ensuring that all relevant procedures for the
conduct of the trial are in place
 Advising the TCC staff on specific aspects as required
 Maintaining the Trial Master File
 Identifying trial sites
 Confirming all approvals are in place before release
of trial treatment and the start of the trial at a site
 Providing training about the trial
 Providing study materials
 Acting as the data management centre
 Providing a 24-h advice and unblinding service
 Giving collaborators regular information about the
progress of the study
 Responding to questions (for example, from
collaborators) about the trial
 Ensuring data security and quality and observe data
protection laws
 Safety reporting
 Ensuring the trial is conducted in accordance with
the ICH GCP
 Statistical analysis
 Publication of trial results
Contacting the Trial Coordinating Centre in an emergency
For urgent enquiries, adverse event reporting and unblind-
ing queries, investigators can contact the 24-h telephone
service provided by the TCC. A central telephone number
is given in the Investigator’s Study File and posters.
Publication and dissemination of results
All efforts will be made to ensure that the trial protocol
and results arising from the CRASH-3 trial are pub-
lished in an established peer-reviewed journal. At least
one publication of the main trial results will be made.
On reflection this information is not needed – too much
detail. Links to the publication will be provided in all ap-
plicable trial registers. Dissemination of results to
patients will take place via the media, trial website
(http://crash3.Lshtm.ac.uka) and relevant patient organi-
zations. In addition, participants and their families will
be made aware of the trial results if requested. Collabor-
ating investigators will play a vital role in disseminating
the results to colleagues and patients. The success of the
trial will be dependent entirely upon the collaboration of
the nurses and doctors in the participating hospitals and
those who hold key responsibility for the trial. Hence,
the credit for the study will be assigned to the key col-
laborator(s) from each participating site, as it is crucial
that those taking credit for the work have actually car-
ried it out. The results of the trial will be reported first
to trial collaborators. As a large number of hospitals in
many countries will contribute to this trial, individual
countries or sites cannot restrict the publication of the
manuscript relating to the outcomes of this trial. An-
onymous data for this trial will be made available for free
use at http://freebird.lshtm.ac.uk.b
Financial support
The JP Moulton Charitable Trust, UK, is funding the
run-in costs for this trial and up to 500 patients’ recruit-
ment. Full funding is being sought from public funding
organizations for the main trial. Funding for this trial
covers meetings and central organizational costs only.
The design and management of the study are entirely in-
dependent of the manufacturers of TXA or the funders.
Large trials of drugs such as TXA, involving many
hospitals, are important for future patients, but are prac-
ticable only if those collaborating in them do so without
payment (except for recompense of any minor local
costs that may arise). Agreement for repayment of local
costs will be made in advance. This trial will not gener-
ate any intellectual property for the Sponsor or collabor-
ating institutions. The trial plans to include over 250
hospitals in about 40 countries. Review by each Ethics
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Committee and Regulatory Agency would create a sub-
stantial financial burden which could limit the conduct
of the trial. We request that payment for review of the
protocol by each Committee be waived or set at a rea-
sonable rate to reflect the actual cost of reviewing the
trial protocol.
Trial status
Ethics approval obtained from several institutions. Na-
tional ethics and regulatory approvals are in progress in
10 countries. Patient recruitment is planned to take place
in over 30 countries and is due to start in April 2012.
End of recruitment is planned for 31 December 2016
with end of follow-up due 31 January 2017. Further in-
formation is available at http://crash3.lshtm.ac.uk/
Additional files
Additional file 1: Form 1. Entry form.
Additional file 2: Form 2. Ou form.
Additional file 3: Form 3. Brief intcomeformation leaflet for relatives.
Additional file 4: Form 4. Information sheet for the patient and
representative.
Additional file 5: Form 5. Consent form for the patient and
representative.
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